Editor's Note: The Fierce PM Tracker will not publish Monday, Jan. 20, in observance of Martin Luther King Jr. Day. We’ll be back in your inbox Jan. 21.
Approaching early development strategically is critical to the later success of a drug candidate. Discover the current challenges and considerations for biotechs to maximize drug development outcomes.
If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency.
In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at 72 weeks compared to placebo or semaglutide 2.4 mg, which is currently the highest dose of Novo Nordisk's drug marketed under the Wegovy brand for obesity.
This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties following the fatal shooting of UnitedHealthcare’s CEO in December.
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act. The list of 15 medicines includes blockbuster drugs from Novo Nordisk, Pfizer, Bristol Myers Squibb, AstraZeneca, GSK and other companies. Novo’s booming semaglutide franchise for diabetes and obesity is the standout inclusion in this year's list.
This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
Bristol Myers Squibb vet Catherine Owen Adams joined Acadia Pharmaceuticals in September on the heels of the company's new rare disease launch and its scrapped label expansion push for troubled Nuplazid.
By Andrea Park,Fraiser Kansteiner,Gabrielle Masson
This week on “The Top Line,” we explore the trends that defined the industry in 2024 and predict how 2025 might shake out for biopharmas big and small.
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase eightfold in a decade as therapies address unmet medical need.
After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran exec will depart on Feb. 21 to lead a private biotech company.
This week on “The Top Line,” we explore the trends that defined the industry in 2024 and predict how 2025 might shake out for biopharmas big and small.
How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights.
Presented by: Blue Matter, strategic consultants in the life sciences
